The Infliximab Rheumatoid Arthritis Methotrexate Tapering (iRAMT) Protocol
Information source: Centocor Ortho Biotech Services, L.L.C.
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Arthritis, Rheumatoid
Intervention: infliximab (Drug)
Phase: Phase 4
Status: Completed
Sponsored by: Centocor Ortho Biotech Services, L.L.C. Official(s) and/or principal investigator(s): Centocor Ortho Biotech Services, L.L.C. Clinical Trial, Study Director, Affiliation: Centocor Ortho Biotech Services, L.L.C.
Summary
The purpose of the study was to evaluate the ability of a maintenance dosage regimen of
infliximab to achieve and sustain at least 40% improvement from baseline in the total joint
count in patients with active Rheumatoid Arthritis (RA) during methotrexate tapering.
Clinical Details
Official title: The Infliximab Rheumatoid Arthritis Methotrexate Tapering (iRAMT) Protocol. Tapering Methotrexate in Patients With Rheumatoid Arthritis Beginning Therapy With Infliximab
Study design: Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: The primary efficacy endpoint is the number (%) of patients on a maintenance dose of infliximab who achieve at least 40% improvement from baseline in the combined tender and swollen joint count and tolerate any reduction in MTX dose at Week 54
Secondary outcome: Sustained improvement in signs and symptoms of RA at Week 54, as measured by the percentage improvement from baseline in ACR20 score. Improvement of the ACR20 core set components at Week 54.
Detailed description:
Rheumatoid arthritis (RA) is a chronic autoimmune disorder of unknown etiology that occurs
in approximately one percent of the population. Current therapy for RA comprises
non-steroidal anti-inflammatory drugs (NSAIDs) in early stages of the disease, ultimately
giving way to oral glucocorticoids and the disease-modifying anti-rheumatic drugs (DMARDs)
as the disease progressively worsens. Therapy with DMARDs (e. g., D-penicillamine, auranofin,
hydroxychloroquine, azathioprine, methotrexate) is not ideal in that they generally have a
slow onset of action (measured in months), variable levels of effectiveness, and
dose-limiting toxicity. Methotrexate (MTX) has become the DMARD of choice of many
rheumatologists because of its faster mode of action and better record of prolonged use.
However, despite the use of high doses of MTX, many patients only experience partial relief
of symptoms and still have features of active disease. The current product labeling provides
for a range of infliximab doses. Four fixed maintenance dose regimens proved to be safe and
efficacious in the Anti-TNF Trial in Rheumatoid Arthritis with Concomitant Therapy (ATTRACT)
trial. However, the efficacy of incremental dose titration in patients with RA who have not
achieved or maintained a clinically important improvement from baseline status has not been
established in a clinical trial setting. Additionally, whether MTX tapering is possible in
those patients who have achieved a clinically important improvement from baseline status has
not been demonstrated. The iRAMT trial utilizes a prescribed strategy for infliximab dose
titration in the event that individuals do not achieve a 40% improvement in the combined
swollen and tender joint count, or have a disease flare or recurrent worsening. The iRAMT
trial defines a clinically important improvement as at least a 40% improvement from
baseline. Once the 40% improvement is achieved, MTX tapering will be initiated as
appropriate for the specific patient. The primary efficacy endpoint is the number (%) of
patients on a maintenance dose of infliximab who achieve at least 40% improvement from
baseline in the combined tender and swollen joint count and tolerate any reduction in MTX
dose at Week 54. Hence, this trial will provide information regarding an infliximab dose
titration strategy as well as a MTX tapering schedule in those patients responding to
therapy. The iRAMT trial will examine, in a manner consistent with clinical practice, if a
schedule of infliximab maintenance will allow for tapering of MTX to occur. Patients will
receive Infliximab infusions at a minimum dose of 3 mg/kg at Weeks 0, 2, 6 and every 8 weeks
thereafter until Week 46. During the study, the dose of infliximab may be increased by
single 100-mg vials using a specified regimen up to a maximum of 10 mg/kg every 4 weeks.
Eligibility
Minimum age: 18 Years.
Maximum age: 80 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Previous diagnosis of RA according to the revised 1987 criteria of the American
Rheumatism Association (Arnett et al., 1988)
- patients must have a minimum of 8 tender and 4 swollen joints with disease diagnosed
at least 3 months prior to screening
- patients must have been using oral or parenteral MTX for at least the previous 3
months, and at a stable dose of 7. 5 to 25 mg per week for at least the previous 1
month
- women of childbearing potential must test negative for pregnancy and be using
adequate birth control measures
- patients must have a documented purified protein derivative (PPD) skin test performed
at prescreening.
Exclusion Criteria:
- Patients who have received any prior treatment with infliximab or with any other
therapeutic agent targeted at reducing tumor necrosis factor (TNF) (e. g., etanercept,
pentoxifylline or thalidomide) within the previous 3 months
- patients who are incapacitated
- history of infected joint prosthesis within the previous 5 years
- patients with a concomitant diagnosis of congestive heart failure (CHF), history of
or known malignancy within the previous 5 years, cases of active or latent
tuberculosis (TB), acute or chronic serious infections within the past 3 months
- known substance abuse (drug or alcohol) within the previous 3 years
Locations and Contacts
Additional Information
The Infliximab Rheumatoid Arthritis Methotrexate Tapering (iRAMT) Protocol. Tapering Methotrexate in Patients with Rheumatoid Arthritis Beginning Therapy with Infliximab.
Starting date: December 2001
Last updated: May 18, 2011
|